Supporting individuals with Alzheimer's disease and those that care for them
Dthera Sciences (OTCQB: DTHR) is a publicly traded digital therapeutics company focused on the elderly and individuals with neurodegenerative diseases.
The Alzheimer's Disease Healthcare Crisis
5.7 million Americans are living with Alzheimer’s disease. By 2050, this number is projected to rise to to nearly 14 million
Digital Therapeutics
Digitizing evidence-based cognitive-behavioral therapies and delivering them at scale
Breakthrough Device Designation
DTHR-ALZ is the first product to receive Breakthrough Device designation from the FDA
for the treatment of Alzheimer’s disease
Press and media
Latest news
Dthera Sciences Chief Technology Officer to Speak at CES Digital Health Summit
Dave Keene, Co-Founder and Chief Technology Officer will be speaking at CES, Digital Health Summit, A Brain and Mental Health Crisis Intervention. CES 2019, is January 8-11, 2019 in Las Vegas
Dthera Sciences to Provide Corporate Update at the Digital Medicine and Medtech Showcase
Dthera™ Sciences (OTCQB:DTHR), the leading digital therapeutic company focusing on the elderly, will be presenting at the Digital Medicine and MedTech Showcase 2019 on Tuesday, January 8 at 10:30am PST in San Francisco.
Connect with us
Subscribe to our e-mail list and stay up-to-date with all our news.